A second mismatch sits underneath the first. Traditional EEG monitoring typically runs for up to 72 hours. Seizures can occur days or weeks apart, and most produce no outward physical signs.

A test lasting three days is therefore hunting an event that might not arrive for a month. Diagnosis can take months as a result.

What the device actually is

REMI uses four disposable wearable sensors and records for up to 30 days. Data travels to Persyst Mobile, which Epitel describes as the most common EEG review platform, so neurologists read it in software they already know.

It is not a hospital EEG in miniature. The indications for use describe sensors that transmit “a single channel of electrical activity of the brain”.

Clinical EEG typically uses around 20 electrodes. The research paper Epitel cites on its own site calls the approach a “wearable reduced-channel EEG system”.

That is the trade. Fewer channels, in exchange for weeks of recording in a patient's own home.

The label is narrower than the announcement

Epitel talks about diagnosis, and about AI that helps clinicians accelerate it. The regulatory text is more careful.

REMI “does not make any diagnostic conclusion about the subject's condition and is intended as a physiological signal monitor”, the indications state.

The AI carries similar limits. REMI Vigilenz marks sections that may correspond to potential electrographic seizures lasting at least 10 seconds, for a physician to review. It “does not mark REMI EEG records in real time”.

None of that is unusual for a cleared device. It does mean the system gathers evidence for a neurologist rather than reaching conclusions itself.

The age gap in the AI

The portfolio holds five FDA 510(k) clearances. The most recent extended monitoring down to patients aged one.

The AI did not come with it. REMI monitoring is cleared from age one, while Vigilenz event detection is cleared only from age six.

Young children produce different EEG patterns from adults, so the youngest patients currently get the hardware without the automated review.

The DexCom playbook

Chief executive Steve Pacelli joined from DexCom, a company that spent two decades replacing occasional blood glucose tests with continuous wearable monitoring.

The parallel is close. Epitel wants to do to EEG what continuous glucose monitors did to the finger prick, moving measurement out of the clinic and stretching it across time. DexCom has since become a test case for how the FDA handles that category.

The most useful commercial detail is quieter. REMI is reimbursable under existing billing codes, and new medical devices often stall for years waiting for codes to be created.

What clinicians say

Dr Daniel Friedman, professor and director of the epilepsy division at NYU Langone Health, was quoted in the announcement.

Established tools have been “limited by monitoring duration, as in ambulatory EEG, or by cost and an unnatural setting, as in inpatient video EEG monitoring”, he said. REMI allows tracking “on clinically relevant timescales of days to weeks”.

Joshua Phillips of Catalyst Health Ventures was blunter about the opportunity. “The ambulatory EEG market has needed this kind of disruption for decades,” he said.

Phillips also co-led the round and chairs Epitel's board, so his enthusiasm is not disinterested.

Where it sits

Brain technology attracts money at both extremes. Paradromics has implanted a clinical brain chip for speech, while researchers warn that uneven access to neurotechnology risks becoming a new digital divide.

Smaller cleared devices keep raising too. Tissium took $60m for sutureless nerve repair, and 01Health raised to turn specialist care into infrastructure.

Epitel sits at the unglamorous end, and that is rather the point. A four-sensor patch worn at home is a smaller idea than an implant, and it reaches far more people.